ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 282,69
0,14%
Dow Jones
43 297,03
0,91%
DAX
19 848,77
-0,34%
Brent Oil
73,285
0,00%
Bitcoin
98 424,68
-0,26%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Y mAbs Therapeutics Inc (YMAB) Cours

Y mAbs Therapeutics Inc

Y mAbs Therapeutics Inc (YMAB)

NASDAQ
8,15
0,04
(0,49%)
À la fermeture: 25 Décembre 10:00PM
Retardé de 15 minutes
8,15
0,00
( 0,00% )
Après les heures de négociation: 10:01PM
Retardé de 15 minutes

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
8,15
Prix Achat
7,34
Prix Vente
9,02
Volume échangé
150 225
7,80 Fourchette du Jour 8,225
6,48 Plage de 52 semaines 20,90
Cap du marché
365,031M
Clôture Veille
8,11
Ouverture
8,13
Dernière Transaction
5
@
8.21
Dernière heure de transaction
Volume financier
US$ 1 219 078
VWAP
8,115
Volume moyen (3 m)
255 151
Actions en circulation
44 789 076
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-17,04
Bénéfice par action (BPA)
-0,48
Chiffre d'affairess
84,82M
Bénéfice net
-21,43M

À propos de Y mAbs Therapeutics Inc

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Its pipeline covers Naxitamab, Omburtamab, GD2-GD3 Vaccine, and others. Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Its pipeline covers Naxitamab, Omburtamab, GD2-GD3 Vaccine, and others.

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.ymabs.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Y mAbs Therapeutics Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker YMAB. Le dernier cours de clôture d'Y mAbs Therapeutics était de US$8,11. Au cours de la dernière année, les actions de Y mAbs Therapeutics ont été négociées dans une fourchette de prix de US$ 6,48 à US$ 20,90.

Y mAbs Therapeutics compte actuellement 44 789 076 actions en circulation. La capitalisation boursière d'Y mAbs Therapeutics est de US$363,24 million. Y mAbs Therapeutics a un ratio cours/bénéfice (ratio PE) de -17.04.

YMAB Dernières nouvelles

Plus de nouvelles

Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...

23 Décembre 2024
GlobeNewswire Inc.

Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting

NEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...

07 Décembre 2024
GlobeNewswire Inc.

Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...

27 Novembre 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 Novembre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

08 Novembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

08 Novembre 2024
Edgar (US Regulatory)

Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments

Reported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024Entered into exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan...

08 Novembre 2024
GlobeNewswire Inc.

Form 8-K - Current report

04 Novembre 2024
Edgar (US Regulatory)

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan

NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...

04 Novembre 2024
GlobeNewswire Inc.

Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast

NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...

25 Octobre 2024
GlobeNewswire Inc.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-1.69-17.1747967489.849.967.874696528.51911059CS
4-2.39-22.675521821610.5412.47.873087669.66834218CS
12-4.97-37.88109756113.1216.117.8725515111.98207433CS
26-3.9-32.365145228212.0516.117.8726228312.4436263CS
521.2518.1159420296.920.96.4832057613.05708018CS
156-9.045-52.60250072717.19520.92.74130149.33879335CS
260-24.62-75.129691791332.7755.362.733875816.20899691CS

YMAB - Frequently Asked Questions (FAQ)

What is the current Y mAbs Therapeutics share price?
The current share price of Y mAbs Therapeutics is US$ 8,15
How many Y mAbs Therapeutics shares are in issue?
Y mAbs Therapeutics has 44 789 076 shares in issue
What is the market cap of Y mAbs Therapeutics?
The market capitalisation of Y mAbs Therapeutics is USD 363,24M
What is the 1 year trading range for Y mAbs Therapeutics share price?
Y mAbs Therapeutics has traded in the range of US$ 6,48 to US$ 20,90 during the past year
What is the PE ratio of Y mAbs Therapeutics?
The price to earnings ratio of Y mAbs Therapeutics is -17,04
What is the cash to sales ratio of Y mAbs Therapeutics?
The cash to sales ratio of Y mAbs Therapeutics is 4,3
What is the reporting currency for Y mAbs Therapeutics?
Y mAbs Therapeutics reports financial results in USD
What is the latest annual turnover for Y mAbs Therapeutics?
The latest annual turnover of Y mAbs Therapeutics is USD 84,82M
What is the latest annual profit for Y mAbs Therapeutics?
The latest annual profit of Y mAbs Therapeutics is USD -21,43M
What is the registered address of Y mAbs Therapeutics?
The registered address for Y mAbs Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Y mAbs Therapeutics website address?
The website address for Y mAbs Therapeutics is www.ymabs.com
Which industry sector does Y mAbs Therapeutics operate in?
Y mAbs Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
BAOSBaosheng Media Group Holdings Ltd
US$ 7,10
(310,40%)
58,74M
HOURHour Loop Inc
US$ 4,40
(207,69%)
97,42M
GTIGraphjet Technology
US$ 0,61
(168,72%)
265,48M
CREVCarbon Revolution Public Ltd
US$ 9,16
(135,48%)
26,95M
AVGRAvinger Inc
US$ 1,45
(125,72%)
107,53M
SLGLSol Gel Technologies Ltd
US$ 0,9798
(-40,62%)
3,07M
DRCTDirect Digital Holdings Inc
US$ 3,71
(-32,55%)
23,82M
CHEKCheck Cap Ltd
US$ 1,55
(-31,11%)
3,49M
SYTASiyata Mobile Inc
US$ 0,5178
(-30,83%)
2,63M
BTFValkyrie ETF Trust II CoinShares Bitcoin and Ether Stratagy ETF
US$ 15,47
(-30,38%)
147,98k
SVMHSRIVARU Holding Ltd
US$ 0,0338
(20,71%)
280,27M
GTIGraphjet Technology
US$ 0,61
(168,72%)
265,48M
LITMSnow Lake Resources Ltd
US$ 0,5849
(52,84%)
181,22M
LCIDLucid Group Inc
US$ 3,20
(3,23%)
108,75M
RGTIRigetti Computing Inc
US$ 11,35
(3,56%)
108,38M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
YMAB
Y mAbs Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés